At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
cyclosporine ophthalmic emulsion 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
In Brief
A Phase 2 clinical trial evaluating cyclosporine ophthalmic emulsion 0.05% and Vehicle for Pterygium. Completed, enrolled 115 participants across 3 sites in 3 countries.
Detailed Summary
This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPterygium
CountriesAustralia, Singapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJun 2010
Primary CompletionMay 2011
Study CompletionJun 2011
TodayJul 2026
First PostedApr 22, 2010
Enrollment StartJun 1, 2010
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.2 years ago
Interventions
cyclosporine ophthalmic emulsion 0.05%drug
One drop in the study eye (or eyes) administered four times daily (QID)
Vehicledrug
One drop in the study eye (or eyes) administered four times daily (QID)